Skip to content
The Policy VaultThe Policy Vault

Horizant (gabapentin enacarbil)Highmark

Post-Herpetic Neuralgia (PHN)

Preferred products

  • generic gabapentin

Initial criteria

  • age ≥ 18 years
  • diagnosis of PHN (ICD-10: B02.23)
  • therapeutic failure or intolerance to plan preferred generic gabapentin

Reauthorization criteria

  • prescriber attests that the member has experienced positive clinical response to therapy

Approval duration

12 months